Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes

References

• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–480. doi:10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA. Modern radiotherapy for head and neck cancer. Semin Oncol. 2019;46(3):233–245. doi:10.1053/j.seminoncol.2019.07.002
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407–419. doi:10.3892/ijo.2018.4661
   PubMed Web of Science ®Google Scholar
• Scotte F, Ratta R, Beuzeboc P. Side effects of immunotherapy: a constant challenge for oncologists. Curr Opin Oncol. 2019;31(4):280–285. doi:10.1097/CCO.0000000000000541
   PubMed Web of Science ®Google Scholar
• Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and ex vivo strategies for intracellular delivery. Nature. 2016;538(7624):183–192. doi:10.1038/nature19764
   PubMed Web of Science ®Google Scholar
• Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, Prosperi D. Thirty years of cancer nanomedicine: success, frustration, and hope. Cancers. 2019;11(12):1855. doi:10.3390/cancers11121855
   PubMed Web of Science ®Google Scholar
• Kue CS, Kamkaew A, Burgess K, Kiew LV, Chung LY, Lee HB. Small molecules for active targeting in cancer. Med Res Rev. 2016;36(3):494–575. doi:10.1002/med.21387
   PubMed Web of Science ®Google Scholar
• Akhavan O, Ghaderi E. Graphene nanomesh promises extremely efficient in vivo photothermal therapy. Small. 2013;9(21):3593–3601. doi:10.1002/smll.201203106
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Chattopadhyay D, Kappel BJ, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med. 2007;48(7):1180–1189. doi:10.2967/jnumed.106.039131
   PubMed Web of Science ®Google Scholar
• Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of ”stealthy” nanomaterials. Front Bioeng Biotechnol. 2020;8:166. doi:10.3389/fbioe.2020.00166
   PubMed Web of Science ®Google Scholar
• Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule Corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):37–43. doi:10.1038/nnano.2012.237
   Web of Science ®Google Scholar
• Mirshafiee V, Kim R, Park S, Mahmoudi M, Kraft ML. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials. 2016;75:295–304. doi:10.1016/j.biomaterials.2015.10.019
   PubMed Web of Science ®Google Scholar
• Mirshafiee V, Mahmoudi M, Lou K, Cheng J, Kraftm ML. Protein corona significantly reduces active targeting yield. Chem Commun. 2013;49(25):2557–2559. doi:10.1039/c3cc37307j
   PubMed Web of Science ®Google Scholar
• Dai Q, Yan Y, Guo J, et al. Targeting ability of affibody-functionalized particles is enhanced by albumin but inhibited by serum coronas. ACS Macro Lett. 2015;4(11):1259–1263. doi:10.1021/acsmacrolett.5b00627
   PubMed Web of Science ®Google Scholar
• Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020;10(4):787. doi:10.3390/nano10040787
   Web of Science ®Google Scholar
• Peng Q, Zhang S, Yang Q, et al. Preformed albumin Corona, a protective coating for nanoparticles based drug delivery system. Biomaterials. 2013;34(33):8521–8530. doi:10.1016/j.biomaterials.2013.07.102
   PubMed Web of Science ®Google Scholar
• Zhu Y, Chen C, Cao Z, et al. On-demand PEGylation and dePEGylation of PLA-based nanocarriers via amphiphilic mPEG-TK-Ce6 for nanoenabled cancer chemotherapy. Theranostics. 2019;9(26):8312–8320. doi:10.7150/thno.37128
   PubMed Web of Science ®Google Scholar
• Pinals RL, Chio L, Ledesma F, Landry MP. Engineering at the nano-bio interface: harnessing the protein corona towards nanoparticle design and function. Analyst. 2020;145(15):5090–5112. doi:10.1039/D0AN00633E
   PubMed Web of Science ®Google Scholar
• Hajipour MJ, Raheb J, Akhavan O, et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale. 2015;7(19):8978–8994. doi:10.1039/C5NR00520E
   PubMed Web of Science ®Google Scholar
• Corbo C, Molinaro R, Tabatabaei M, Farokhzad OC, Mahmoudi M. Personalized protein Corona on nanoparticles and its clinical implications. Biomater Sci. 2017;5(3):378–387. doi:10.1039/C6BM00921B
   PubMed Web of Science ®Google Scholar
• Uebe R, Schuler D. Magnetosome biogenesis in magnetotactic bacteria. Nat Rev Microbiol. 2016;14(10):621–637. doi:10.1038/nrmicro.2016.99
   PubMed Web of Science ®Google Scholar
• Alphandéry E. Applications of magnetosomes synthesized by magnetotactic bacteria in medicine. Front Bioeng Biotechnol. 2014;2:5. doi:10.3389/fbioe.2014.00005
   PubMedGoogle Scholar
• Nan X, Teng Y, Tian J, Hu Z, Fang Q. A comprehensive assessment of the biocompatibility of Magnetospirillum gryphiswaldense MSR-1 bacterial magnetosomes in vitro and in vivo. Toxicology. 2021;462:152949. doi:10.1016/j.tox.2021.152949
   PubMed Web of Science ®Google Scholar
• Han L, Li S, Yang Y, Zhao F, Huang J, Chang J. Comparison of magnetite nanocrystal formed by biomineralization and chemosynthesis. J Magn Magn Mater. 2007;313(1):236–242. doi:10.1016/j.jmmm.2007.01.004
   Web of Science ®Google Scholar
• Nygren PÅ. Alternative binding proteins: affibody binding proteins developed from a small three‐helix bundle scaffold. FEBS J. 2008;275(11):2668–2676. doi:10.1111/j.1742-4658.2008.06438.x
   PubMed Web of Science ®Google Scholar
• Gebauer M, Skerra A. Engineered protein scaffolds as next-generation therapeutics. Annu Rev Pharmacol Toxicol. 2020;60:391–415. doi:10.1146/annurev-pharmtox-010818-021118
   PubMed Web of Science ®Google Scholar
• Liu J, Ding Y, Jiang W, Tian J, Li Y, Li J. A mutation upstream of an ATPase gene significantly increases magnetosome production in Magnetospirillum gryphiswaldense. Appl Microbiol Biotechnol. 2008;81(3):551–558. doi:10.1007/s00253-008-1665-1
   PubMed Web of Science ®Google Scholar
• Xu J, Liu L, He J, et al. Engineered magnetosomes fused to functional molecule (protein A) provide a highly effective alternative to commercial immunomagnetic beads. J Nanobiotechnology. 2019;17(1):37. doi:10.1186/s12951-019-0469-z
   PubMed Web of Science ®Google Scholar
• Guo F, Liu Y, Chen Y, et al. A novel rapid and continuous procedure for large-scale purification of magnetosomes from Magnetospirillum gryphiswaldense. Appl Microbiol Biotechnol. 2011;90(4):1277–1283. doi:10.1007/s00253-011-3189-3
   PubMed Web of Science ®Google Scholar
• Geng Y, Wang J, Wang X, et al. Growth-inhibitory effects of anthracycline-loaded bacterial magnetosomes against hepatic cancer in vitro and in vivo. Nanomedicine. 2019;14(13):1663–1680. doi:10.2217/nnm-2018-0296
   PubMed Web of Science ®Google Scholar
• Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68(5):850–858. doi:10.1021/ac950914h
   PubMed Web of Science ®Google Scholar
• Ishihama Y, Oda Y, Tabata T. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4(9):1265–1272. doi:10.1074/mcp.M500061-MCP200
   PubMed Web of Science ®Google Scholar
• Kapingidza AB, Kowal K, Chruszcz M. Antigen-antibody complexes. Subcell Biochem. 2020;94:465–497.
   PubMedGoogle Scholar
• Waldmann H. Human monoclonal antibodies: the benefits of humanization. Methods Mol Biol. 2019;1904:1–10.
   PubMedGoogle Scholar
• Tripathi K, Driskell JD. Quantifying bound and active antibodies conjugated to gold nanoparticles: a comprehensive and robust approach to evaluate immobilization chemistry. ACS Omega. 2018;3(7):8253–8259. doi:10.1021/acsomega.8b00591
   PubMed Web of Science ®Google Scholar
• Monopoli MP, Walczyk D, Campbell A, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc. 2011;133(8):2525–2534. doi:10.1021/ja107583h
   PubMed Web of Science ®Google Scholar
• Nierenberg D, Khaled AR, Flores O. Formation of a protein corona influences the biological identity of nanomaterials. Rep Pract Oncol Radiother. 2018;23(4):300–308. doi:10.1016/j.rpor.2018.05.005
   PubMedGoogle Scholar
• Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev. 1992;3(2):101–121.
   PubMedGoogle Scholar
• Mota AL, Evangelista AF, Macedo T, et al. Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. Oncol Lett. 2017;13(6):4708–4712. doi:10.3892/ol.2017.6093
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285–4289. doi:10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Hall AP, Davies W, Stamp K, Clamp I, Bigley A. Comparison of computerized image analysis with traditional semiquantitative scoring of Perls’ Prussian Blue stained hepatic iron deposition. Toxicol Pathol. 2013;41(7):992–1000. doi:10.1177/0192623313476576
   PubMed Web of Science ®Google Scholar
• Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17(15–16):850–860. doi:10.1016/j.drudis.2012.03.002
   PubMed Web of Science ®Google Scholar
• Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–967. doi:10.1038/s41551-021-00698-w
   PubMed Web of Science ®Google Scholar
• Marrocco I, Romaniello D, Yarden Y. Cancer immunotherapy: the Dawn of antibody cocktails. Methods Mol Biol. 2019;1904:11–51.
   PubMedGoogle Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13(1):1860476. doi:10.1080/19420862.2020.1860476
   PubMed Web of Science ®Google Scholar
• Sousa F, Castro P, Fonte P, et al. Nanoparticles for the delivery of therapeutic antibodies: dogma or promising strategy? Expert Opin Drug Deliv. 2017;14(10):1163–1176. doi:10.1080/17425247.2017.1273345
   PubMed Web of Science ®Google Scholar
• Peng XH, Qian X, Mao H, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomed. 2008;3(3):311–321. doi:10.2147/ijn.s2824
   PubMed Web of Science ®Google Scholar
• Alphandery E. Applications of magnetotactic bacteria and magnetosome for cancer treatment: a review emphasizing on practical and mechanistic aspects. Drug Discov Today. 2020;25(8):1444–1452. doi:10.1016/j.drudis.2020.06.010
   PubMed Web of Science ®Google Scholar
• Lai W, Li D, Wang Q, et al. A protein Corona adsorbed to a bacterial magnetosome affects its cellular uptake. Int J Nanomedicine. 2020;15:1481–1498. doi:10.2147/IJN.S220082
   PubMed Web of Science ®Google Scholar
• Kopac T. Protein corona, understanding the nanoparticle-protein interactions and future perspectives: a critical review. Int J Biol Macromol. 2021;169:290–301. doi:10.1016/j.ijbiomac.2020.12.108
   PubMed Web of Science ®Google Scholar
• Di Santo R, Digiacomo L, Quagliarini E, et al. Personalized graphene oxide-protein corona in the human plasma of pancreatic cancer patients. Front Bioeng Biotechnol. 2020;8:491. doi:10.3389/fbioe.2020.00491
   PubMed Web of Science ®Google Scholar
• Caputo D, Papi M, Coppola R, et al. A protein Corona-enabled blood test for early cancer detection. Nanoscale. 2017;9(1):349–354. doi:10.1039/C6NR05609A
   PubMed Web of Science ®Google Scholar
• Hu W, Peng C, Lv M, et al. Protein Corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano. 2011;5(5):3693–3700. doi:10.1021/nn200021j
   PubMed Web of Science ®Google Scholar
• Mbeh DA, Akhavan O, Javanbakht T, Mahmoudi M, Yahia L. Cytotoxicity of protein Corona-graphene oxide nanoribbons on human epithelial cells. Appl Surf Sci. 2014;320:596–601. doi:10.1016/j.apsusc.2014.09.155
   Web of Science ®Google Scholar
• Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7(12):779–786. doi:10.1038/nnano.2012.207
   PubMed Web of Science ®Google Scholar
• Ye ELL, Joshua U, Cheah J, et al. Exploiting the protein Corona around gold nanorods for low-dose combined photothermal and photodynamic therapy. J Mater Chem B. 2017;5(2):254–268. doi:10.1039/C6TB02743A
   PubMed Web of Science ®Google Scholar
• Hajipour MJ, Akhavan O, Meidanchi A, Laurent S, Mahmoudi M. Hyperthermia-induced protein Corona improves the therapeutic effects of zinc ferrite spinel-graphene sheets against cancer. RSC Adv. 2014;4(107):62557–62565. doi:10.1039/C4RA10862K
   Web of Science ®Google Scholar
• Assali A, Razzazan S, Akhavan O, Mottaghitalab F, Adeli M, Atyabi F. The bio-interface between functionalized Au NR@ GO nanoplatforms with protein Corona and their impact on delivery and release system. Colloids Surf B Biointerfaces. 2019;173:89–1898.
   Web of Science ®Google Scholar
• Yeo ELL, Thong PSP, Soo KC, Kah JCY. Protein corona in drug delivery for multimodal cancer therapy in vivo. Nanoscale. 2018;10(5):2461–2472. doi:10.1039/C7NR08509E
   PubMed Web of Science ®Google Scholar
• Haghighi AH, Khorasani MT, Faghih Z, Farjadian F. Effects of different quantities of antibody conjugated with magnetic nanoparticles on cell separation efficiency. Heliyon. 2020;6(4):e03677. doi:10.1016/j.heliyon.2020.e03677
   PubMed Web of Science ®Google Scholar
• Jeong S, Park JY, Cha MG, et al. Highly robust and optimized conjugation of antibodies to nanoparticles using quantitatively validated protocols. Nanoscale. 2017;9(7):2548–2555. doi:10.1039/C6NR04683E
   PubMed Web of Science ®Google Scholar
• Akhavan O, Ghaderi E, Akhavan A. Size-dependent genotoxicity of graphene nanoplatelets in human stem cells. Biomaterials. 2012;33(32):8017–8025. doi:10.1016/j.biomaterials.2012.07.040
   PubMed Web of Science ®Google Scholar
• Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J Appl Toxicol. 2009;29(1):69–78. doi:10.1002/jat.1385
   PubMed Web of Science ®Google Scholar
• Hamdous Y, Chebbi I, Mandawala C, et al. Biocompatible coated magnetosome minerals with various organization and cellular interaction properties induce cytotoxicity towards RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field. J Nanobiotechnology. 2017;15(1):1–18. doi:10.1186/s12951-017-0293-2
   PubMed Web of Science ®Google Scholar
• Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:1–15. doi:10.1155/2012/980250
   Google Scholar